4th Quarter - Termination
ZIRKELBACH STRATEGIES for AMAG PHARMACEUTICALS
Client
Income
$15,000
Expenses
—
Terminated
Oct 31, 2022
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pharmaceutical issues related to womens health product access and education on the accelerated approval pathway
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY KATHLEEN ZIRKELBACH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.